Mesoblast hits 50% enrolment for back pain trial
18 April, 2012 by Dylan Bushell-EmblingMesoblast (ASX:MSB) has enrolled half the patients for a US trial of off the shelf stem cells to restore degenerated intervertebral discs.
Living Cell taps lead investigator for NTCELL trial
18 April, 2012 by Dylan Bushell-EmblingParkinson's expert Dr Barry Snow has agreed to become the lead investigator for a NZ trial of Living Cell Technologies' (ASX:LCT) NTCELL treatment candidate.
Osprey Medical completes $20m ASX IPO
18 April, 2012 by Dylan Bushell-EmblingUS-based medical device company Osprey Medical (ASX:OSP) has completed its $20m IPO on the ASX.
Australian biotechs bullish despite economy and policy concerns
18 April, 2012 by Tim DeanThe AusBiotech Biotechnology Industry Position Survey has found Australian biotechs are optimistic about growth despite concerns over the economic and political environment.
Application for registration under the R&D Tax Incentive
17 April, 2012 by AusBiotechAusIndustry has launched a new publication outlining what will be required when businesses commence registering for the R&D Tax Incentive from 1 July 2012.
Pharmaxis asthma treatment found safe, but is it effective?
17 April, 2012 by Tim DeanA phase IIa trial of Pharmaxis’ (ASX:PXS) experimental allergic asthma drug, ASM8, has been shown safe, but more trials will be required to demonstrate efficacy.
vivoPharm buys RMIT's toxicology business
13 April, 2012 by Dylan Bushell-EmblingRMIT will sell its toxicology testing unit, RDDT, to vivoPharm Technologies in exchange for a 20% stake in the contract research organisation (CRO).
SA Government, via BioSA, funds $1 million IP initiative
12 April, 2012 by AusBiotechThe Government of South Australia has announced it will fund a new $1 million initiative over three years to help South Australia’s three main universities seek patent protection for their intellectual property (IP).
QRxPharma completes trials of MoxDuo CR
11 April, 2012 by Dylan Bushell-EmblingQRxPharma (ASX:QRX) has completed two phase 1 trials of its MoxDuo CR dual-opioid tablets, and revealed some positive pharmacokinetic results.
Sirtex Medical Q3 dose sales grow 34%
11 April, 2012 by Dylan Bushell-EmblingNSW-based biotech Sirtex Medical (ASX:SRX) said Q3 dose sales of its SIR-Spheres microspheres liver cancer treatment a record grew 34% year-on-year.
Brain tumour surgery aid gets orphan drug status
11 April, 2012 by Dylan Bushell-EmblingGliolan, a drug licensed to Melbourne's STA which has the ability to make brain tumours glow red during neurosurgery, has been granted orphan drug status by the TGA.
New institute to lead climate change research
10 April, 2012 by AusBiotechLast week's opening of the Hawkesbury Institute for the Environment at the University of Western Sydney provides Australia with a world-class research institute to tackle the impacts of climate change.
Alchemia partner applies to sell fondaparinux in EU
10 April, 2012 by Dylan Bushell-EmblingDr Reddy's Laboratories has submitted an EU marketing authorisation application covering partner Alchemia's (ASX:ACL) fondaparinux anticoagulant.
Clean Technology Investment Programs open
05 April, 2012 by AusBiotechAusIndustry invites those interested in the new Clean Technology Investment Programs to attend an information session to learn about the programs and how to apply.
Phosphagenics signs Indian skincare licensing deal
05 April, 2012 by Dylan Bushell-EmblingPhosphagenics (ASX:POH) has signed a deal to license two anti-ageing products formulated for the Indian market to Intas Pharmaceuticals.
